The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: A double-blind, placebo-controlled crossover study

Clinical Endocrinology

Volumn 69, Issue 5, 2008, Pages 737-744

  Vella, Adrian ^a,d   Bock, Gerlies ^a   Giesler, Paula D ^a   Burton, Duane B ^a   Serra, Denise B ^b   Saylan, Monica Ligueros ^b   Deacon, Carolyn F ^c   Foley, James E ^b   Rizza, Robert A ^a   Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; PEPTIDE YY; PERTECHNETIC ACID TC 99M; PLACEBO; TECHNETIUM 99M; VILDAGLIPTIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SATIETY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADAMANTANE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRINKING; EATING; ENTEROENDOCRINE CELLS; FASTING; GASTRIC EMPTYING; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; NITRILES; ORGAN SIZE; PLACEBOS; POSTPRANDIAL PERIOD; PYRROLIDINES; SATIATION; STOMACH;

EID: 54049137296     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03235.x     Document Type: Article

References (40)

1. Levine, J.A., Schleusner, S.J. Jensen, M.D. (2000) Energy expenditure of nonexercise activity. American Journal of Clinical Nutrition, 72, 1451 1454.
2. Cummings, D.E. Overduin, J. (2007) Gastrointestinal regulation of food intake. Journal of Clinical Investigation, 117, 13 23.
3. Holst, J.J., Bersani, M., Johnsen, A.H., Kofod, H., Hartmann, B. Orskov, C. (1994) Proglucagon processing in porcine and human pancreas. Journal of Biological Chemistry, 269, 18827 18833.
4. Holst, J.J., Toft-Nielsen, M.B., Orskov, C., Nauck, M. Willms, B. (1996) On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Annals of the New York Academy of Sciences, 805, 729 736.
5. Schirra, J., Wank, U., Arnold, R., Goke, B. Katschinski, M. (2002) Effects of glucagon-like peptide-1 (7-36) amide on motility and sensation of the proximal stomach in humans. Gut, 50, 341 348.
6. Delgado-Aros, S., Kim, D.Y., Burton, D.D., Thomforde, G.M., Stephens, D., Brinkmann, B.H., Vella, A. Camilleri, M. (2002) Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. American Journal of Physiology. Gastrointestinal and Liver Physiology, 282, G424 G431.
7. Delgado-Aros, S., Vella, A., Camilleri, M., Low, P.A., Burton, D.D., Thomforde, G.M. Stephens, D. (2003) Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterological Motility, 15, 435 443.
8. Zander, M., Madsbad, S., Madsen, J.L. Holst, J.J. (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet, 359, 824 830.
9. Heine, R.J., Van Gaal, L.F., Johns, D., Mihm, M.J., Widel, M.H. Brodows, R.G. (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine, 143, 559 569.
10. Nauck, M.A. Meier, J.J. (2005) Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regulatory Peptides, 128, 135 148.
11. Kendall, D.M., Riddle, M.C., Rosenstock, J., Zhuang, D., Kim, D.D., Fineman, M.S. Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28, 1083 1091.
12. Drucker, D.J. (2003) Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opinion on Investigating Drugs, 12, 87 100.
13. Ahren, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.A., Sandqvist, M., Bavenholm, P., Efendic, S., Eriksson, J.W., Dickinson, S. Holmes, D. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 25, 869 875.
14. Vella, A., Bock, G., Giesler, P.D., Burton, D.B., Serra, D.B., Saylan, M.L., Dunning, B.E., Foley, J.E., Rizza, R.A. Camilleri, M. (2007) Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes, 56, 1475 1480.
15. De Meester, I., Durinx, C., Bal, G., Proost, P., Struyf, S., Goossens, F., Augustyns, K. Scharpe, S. (2000) Natural substrates of dipeptidyl peptidase IV. Advances in Experimental Medicine and Biology, 477, 67 87.
16. Batterham, R.L., Cohen, M.A., Ellis, S.M., Le Roux, C.W., Withers, D.J., Frost, G.S., Ghatei, M.A. Bloom, S.R. (2003) Inhibition of food intake in obese subjects by peptide YY3-36. New England Journal of Medicine, 349, 941 948.
17. Batterham, R.L., Le Roux, C.W., Cohen, M.A., Park, A.J., Ellis, S.M., Patterson, M., Frost, G.S., Ghatei, M.A. Bloom, S.R. (2003) Pancreatic polypeptide reduces appetite and food intake in humans. Journal of Clinical Endocrinology and Metabolism, 88, 3989 3992.
18. Flint, A., Raben, A., Ersboll, A.K., Holst, J.J. Astrup, A. (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity and Related Metabolic Disorders, 25, 781 792.
19. Talley, N.J., Phillips, S.F., Melton, J. 3rd., Wiltgen, C. Zinsmeister, A.R. (1989) A patient questionnaire to identify bowel disease. Annals of Internal Medicine, 111, 671 674.
20. Deacon, C.F., Nauck, M.A., Meier, J., Hucking, K. Holst, J.J. (2000) Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. Journal of Clinical Endocrinology and Metabolism, 85, 3575 3581.
21. Cremonini, F., Mullan, B.P., Camilleri, M., Burton, D.D. Rank, M.R. (2002) Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Alimentary Pharmacology and Therapeutics, 16, 1781 1790.
22. Bredenoord, A.J., Chial, H.J., Camilleri, M., Mullan, B.P. Murray, J.A. (2003) Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clinical Gastroenterology and Hepatology, 1, 264 272.
23. DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. Baron, A.D. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092 1100.
24. Ahren, B. (2007) Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care, 30, 1344 1350.
25. Holst, J.J. Deacon, C.F. (2005) Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia, 48, 612 615.
26. Nauck, M.A. El-Ouaghlidi, A. (2005) The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia, 48, 608 611.
27. Hansotia, T., Baggio, L.L., Delmeire, D., Hinke, S.A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J.J., Schuit, F. Drucker, D.J. (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes, 53, 1326 1335.
28. Vazquez Roque, M.I., Camilleri, M., Stephens, D.A., Jensen, M.D., Burton, D.D., Baxter, K.L. Zinsmeister, A.R. (2006) Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology, 131, 1717 1724.
29. Reimann, F. Gribble, F.M. (2002) Glucose-sensing in glucagon-like peptide-1-secreting cells. Diabetes, 51, 2757 2763.
30. Gribble, F.M., Williams, L., Simpson, A.K. Reimann, F. (2003) A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes, 52, 1147 1154.
31. Meier, J.J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J.J., Schmidt, W.E. Nauck, M.A. (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 88, 2719 2725.
32. Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R. Creutzfeldt, W. (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation, 91, 301 307.
33. Meier, J.J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J.J., Schmidt, W.E., Gallwitz, B. Nauck, M.A. (2004) Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. American Journal of Physiology. Endocrinology and Metabolism, 286, E621 E625.
34. Cohen, M.A., Ellis, S.M., Le Roux, C.W., Batterham, R.L., Park, A., Patterson, M., Frost, G.S., Ghatei, M.A. Bloom, S.R. (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. Journal of Clinical Endocrinology and Metabolism, 88, 4696 4701.
35. Chelikani, P.K., Haver, A.C. Reidelberger, R.D. (2004) Comparison of the inhibitory effects of PYY (3-36) and PYY (1-36) on gastric emptying in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 287, R1064 R1070.
36. Deacon, C.F., Wamberg, S., Bie, P., Hughes, T.E. Holst, J.J. (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. Journal of Endocrinology, 172, 355 362.
37. Chaikomin, R., Rayner, C.K., Jones, K.L. Horowitz, M. (2006) Upper gastrointestinal function and glycemic control in diabetes mellitus. World Journal of Gastroenterology, 12, 5611 5621.
38. Hebbard, G.S., Samsom, M., Sun, W.M., Dent, J. Horowitz, M. (1996) Hyperglycemia affects proximal gastric motor and sensory function during small intestinal triglyceride infusion. American Journal of Physiology, 271, G814 G819.
39. Schvarcz, E., Palmer, M., Aman, J. Berne, C. (1995) Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care, 18, 674 676.
40. Schvarcz, E., Palmer, M., Aman, J., Horowitz, M., Stridsberg, M. Berne, C. (1997) Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology, 113, 60 66.